GlassScriptPhysician profile
Kerry Shaughnessy
NPI 1336438753
$10,283.28
in general payments reported to CMS, 2019-2025
36 companies · $1,218 in 2025
The $1,218 reported for 2025 was more than what 79% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,988 · 2020: $1,431 · 2021: $966 · 2022: $1,529 · 2023: $1,680 · 2024: $1,472 · 2025: $1,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,270 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,269.87 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,830.77 | 2019-2025 | Rinvoq, Skyrizi |
| Regeneron Healthcare Solutions, INC. | $1,511.42 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $1,470.01 | 2019-2025 | Tremfya |
| Genzyme Corporation | $766.58 | 2019-2025 | |
| Pfizer INC. | $706.70 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $588.97 | 2019-2025 | |
| Ucb, INC. | $533.50 | 2019-2025 | Bimzelx |
| Leo Pharma INC. | $304.39 | 2019-2025 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $285.75 | 2023-2025 | Spevigo, Cyltezo |
| Amgen INC. | $281.83 | 2020-2025 | Otezla, Otezla |
| Lilly USA, LLC | $279.16 | 2019-2024 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $261.50 | 2019-2025 | Aklief, Oracea, Nemluvio |
| Sun Pharmaceutical Industries INC. | $252.54 | 2019-2024 | Absorica Ld, Winlevi, Odomzo |
| Prugen, INC. Pharmaceuticals | $228.53 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $162.87 | 2022-2024 | Sotyktu |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $89.55 | 2022-2023 | Opzelura |
| Dusa Pharmaceuticals, INC. | $78.94 | 2019 | |
| Dermira, INC. | $78.05 | 2019-2020 | |
| Kerecis Limited | $70.22 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Genentech USA, INC. | $68.73 | 2019-2020 | |
| Almirall LLC | $56.45 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $54.13 | 2019-2020 | |
| Dermavant Sciences, INC. | $45.44 | 2023-2024 | Vtama |
| Celgene Corporation | $34.39 | 2019 | |
| Vyne Pharmaceuticals INC. | $29.53 | 2020 | |
| Smith+Nephew, INC. | $27.56 | 2023 | Grafix Pl |
| Verrica Pharmaceuticals INC. | $26.92 | 2023 | Ycanth |
| Biocon Biologics INC | $24.95 | 2025 | Yesintek |
| Blueprint Medicines Corporation | $24.19 | 2024 | Ayvakit |
| Biofrontera INC. | $20.69 | 2025 | Ameluz |
| Sanofi-Aventis U.S. LLC | $20.64 | 2020 | |
| Mallinckrodt Hospital Products INC. | $19.88 | 2025 | Acthar |
| Mayne Pharma Commercial LLC | $18.03 | 2019 | |
| Organogenesis INC. | $13.77 | 2019 | |
| Mylan Pharmaceuticals INC. | $12.30 | 2019 | |
| Organon LLC | $4.40 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerry Shaughnessy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.